Previous Close | 15.45 |
Open | 15.50 |
Bid | 15.14 x 1100 |
Ask | 15.18 x 800 |
Day's Range | 14.85 - 15.50 |
52 Week Range | 9.15 - 22.44 |
Volume | 175,512 |
Avg. Volume | 176,015 |
Market Cap | 306M |
Beta (3Y Monthly) | 1.28 |
PE Ratio (TTM) | 31.97 |
EPS (TTM) | 0.47 |
Earnings Date | Nov 12, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.00 |
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Q3 2019 Biolife Solutions Inc Earnings Call
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced several executive appointments to further support the integration of Astero Bio, SAVSU Technologies, and Custom Biogenic Systems, three companies acquired during 2019.
Seattle's biotech community has a reputation for developing companies that are eventually acquired and that has restricted its growth. But a few companies are well-positioned to change that narrative.
BOTHELL, Wash., Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the acquisition of substantially all of the assets of Custom Biogenic Systems, Inc. ("CBS"). CBS, a privately held company with operations located near Detroit, is a global leader in the design and manufacture of state-of-the-art liquid nitrogen laboratory freezers and cryogenic equipment.
Third quarter revenue of $6.6 million , up 25% over the prior year Updates 2019 financial guidance to reflect CBS acquisition, introduces preliminary 2020 revenue guidance of $50 to $56 million Conference ...
Today we'll evaluate BioLife Solutions, Inc. (NASDAQ:BLFS) to determine whether it could have potential as an...
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
BOTHELL, Wash. , Nov. 7, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) , a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, ...
BOTHELL, Wash. , Oct. 31, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" ...
Medical Products Industry Outlook: Prospects Seem Promising
In his "Homework" segment of Mad Money Friday night, Jim Cramer followed up on a few stocks that had stumped him during earlier shows. With its products in demand, Cramer said its valuation of 15 times earnings makes it cheap, although he cautioned that the company is small and the stock is speculative. Next, Cramer said that BioLife Solutions is another intriguing biotech play.
Intellectual Property Portfolio Growing with Inventions by Acquired Companies BOTHELL, Wash. , Oct. 14, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of ...
BOTHELL, Wash., Sept. 24, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced a co-investment accelerator program with Casdin Capital, targeting early stage companies that are developing novel cell and gene therapy bioproduction tools. Mike Rice, BioLife Solutions CEO, remarked, "It is increasingly recognized that tools and technology for bioproduction are critical for the successful development and delivery of cell and gene therapies.
BOSTON, Sept. 24, 2019 -- iVexSol, a newly formed viral vector manufacturing company, today announced $2.0 million in new convertible debt funding led by Casdin Capital, LLC.
BOTHELL, Wash., Sept. 16, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced several new customers have adopted the evo cold chain management system in clinical trials targeting cancer and other leading causes of death. The evo system was designed by SAVSU Technologies, which was acquired by BioLife in August 2019. New evo customers joining the previously announced Mustang Bio and Novartis include Adaptimmune, Autolus, Janssen, KBI Pharma, Nanjing Legend and Tessa Therapeutics.
President & CEO of Biolife Solutions Inc (30-Year Financial, Insider Trades) Michael Rice (insider trades) sold 28,571 shares of BLFS on 09/11/2019 at an average price of $19.39 a share. Continue reading...
CFO of Biolife Solutions Inc (30-Year Financial, Insider Trades) Greef Roderick De (insider trades) sold 30,000 shares of BLFS on 09/06/2019 at an average price of $19.78 a share. Continue reading...
Q2 2019 Biolife Solutions Inc Earnings Call
Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders BOTHELL, Wash. , Sept. 3, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio ...
BOTHELL, Wash. , Aug. 28, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, ...
BOTHELL, Wash. , Aug. 12, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class ...
BLFS earnings call for the period ending June 30, 2019.
- Record quarterly revenue of $6.7 million , up 29% over the prior year - Updates 2019 financial guidance to reflect Astero and SAVSU contributions - Conference Call and Webcast Begin at 4:30 pm Eastern ...
BOTHELL, Wash., Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced cold chain management tools for cell and gene therapies. The acquisition is expected to further strengthen BioLife's position as a leading supplier of disruptive, enabling solutions used in the manufacture, storage and distribution of cell and gene therapies.